Concurrent pretibial myxedema and thyroid eye disease following mRNA COVID-19 vaccine in a patient with history of Graves' disease

Philippe Caron; Philippe Imbert; Céline Dekeister; Solange Grunenwald

doi:10.1016/j.ando.2023.10.004

Concurrent pretibial myxedema and thyroid eye disease following mRNA COVID-19 vaccine in a patient with history of Graves' disease

Ann Endocrinol (Paris). 2024 Apr;85(2):100-103. doi: 10.1016/j.ando.2023.10.004. Epub 2023 Oct 20.

Authors

Philippe Caron¹, Philippe Imbert², Céline Dekeister², Solange Grunenwald²

Affiliations

¹ Consultation multidisciplinaire des orbitopathies, Service d'endocrinologie et maladies métaboliques, pôle cardiovasculaire et métabolique, CHU de Larrey, 24, chemin de Pouvourville, TSA 30030, 31059 Toulouse cedex, France. Electronic address: caron.p@chu-toulouse.fr.
² Consultation multidisciplinaire des orbitopathies, Service d'endocrinologie et maladies métaboliques, pôle cardiovasculaire et métabolique, CHU de Larrey, 24, chemin de Pouvourville, TSA 30030, 31059 Toulouse cedex, France.

PMID: 37866430
DOI: 10.1016/j.ando.2023.10.004

Abstract

A 70-year-old female had a history of thyroid surgery for benign nodules and Graves' disease. Following mRNA COVID-19 vaccination, she presented Graves' orbitopathy and pretibial myxedema. Symptoms of thyroid eye disease and thyroid dermopathy improved after 500-mg methylprednisolone infusions.

Keywords: Anti-TSH receptor antibody; Graves’ disease; Pretibial myxedema; SARS-CoV-2 vaccine; Thyroid eye disease; mRNA COVID-19 vaccine.

Publication types

Case Reports

MeSH terms

Aged
COVID-19 Vaccines
COVID-19*
Female
Graves Disease* / diagnosis
Graves Ophthalmopathy*
Humans
Myxedema*
RNA, Messenger

Substances

COVID-19 Vaccines
RNA, Messenger